摘要
新型冠状病毒仍处全球大流行阶段,目前以德尔塔株和奥密克戎株为主要流行毒株,变异株较原始病毒具有更强的传染能力。在抗击疫情过程中,部分社会公共资源和医疗资源可能受影响,部分恶性肿瘤患者就医延迟或中断。在国内外相关研究及临床实践的基础上,中国抗癌协会肿瘤支持治疗专业委员会和中国抗癌协会肿瘤临床化疗专业委员会结合我国国情及疫苗、抗病毒药物等资源的可及性,制定了实体肿瘤患者防护和诊治管理相关问题的中国专家共识,主要内容包括恶性肿瘤患者的新冠疫苗接种、优化调配医疗资源以及精准把握肿瘤患者新冠病毒感染后的抗肿瘤治疗重启时机等内容,旨在为临床提供参考。
The new coronavirus is still in the global pandemic stage.At present,the Delta strain and the Omicron strain are the main circulating strains.The mutant strain has stronger infectivity than the original virus.In the content of COVID-19 pandemic,social public resources and medical resources may be affected,which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors.Based on relevant research and clinical practice at home and abroad,the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association,in the light of China′s national conditions and the availability of resources such as vaccines and antiviral drug,to formulate a consensus of Chinese experts on issues related to the prevention,treatment and management of patients with solid tumors.The main contents include the vaccination of cancer patients with COVID-19,the optimization of medical resources,and the timing of restarting anti-tumor therapy after COVID-19 infection.This article is aimed at providing reference for clinical practice.
作者
中国抗癌协会肿瘤支持治疗专业委员会
中国抗癌协会肿瘤临床化疗专业委员会
巴一
张俊
石远凯
Committee of Neoplastic Supportive-Care,China Anti-Cancer Association;Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association;Ba Yi;Zhang Jun(不详;Department of Digestive Oncology,National Clinical Research Center of Cancer,Tianjin's Clinical Research Center for Cancer,Tianjin's Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Oncology,Rui Jin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2022年第10期1083-1090,共8页
Chinese Journal of Oncology
